News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Mynet Finans Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AnaptysBio (ANAB) has experienced significant share price swings but is considered undervalued by analysts and intrinsic value estimates, trading at a discount despite strong longer-term momentum. The company, focused on immunology therapeutics, is projected to have a fair value of $90 due to rising …
AnaptysBio, now operating as Anaptys, is set to release its Q2 earnings, marking its first full quarter as a pure-play royalty management company after spinning off its drug development operations. Analysts predict a loss of 13 cents per share on $20.2 million in revenue, …
AnaptysBio (ANAB) has awarded its President and CEO, Daniel Faga, 53,334 performance stock units (PSUs). These PSUs were granted after meeting specific performance criteria and will vest over two years, with 50% vesting on March 12, 2027, and the remaining 50% on March 12, …
AnaptysBio (NASDAQ: ANAB) has awarded 16,667 performance stock units (PSUs) to its Chief Medical Officer, Paul F. Lizzul. These PSUs were granted on March 12, 2026, after achieving certified performance criteria, with each unit representing a right to one share of common stock. The …
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $82.00. Despite missing quarterly earnings per share estimates, the company exceeded revenue expectations. Several institutions have recently increased their holdings in AnaptysBio stock.
AnaptysBio (ANAB) has entered a key post-trial phase in its legal dispute with Tesaro and GlaxoSmithKline, involving allegations of material breach of contract and tortious interference. Following a trial in July 2026, a schedule for post-trial briefing and argument has been set, with key …
AnaptysBio announced the post-trial briefing schedule following its July 2026 litigation with Tesaro and GlaxoSmithKline. A Joint Stipulation was granted by the Court, setting deadlines for briefs, with AnaptysBio filing its opening brief by August 21, 2026. Oral arguments are scheduled for October 20, …
AnaptysBio Inc (ANAB) has a strong financial score of 7.86, placing it high within the Biotechnology & Medical Research industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue and net profit experienced year-over-year decreases of 7.98% and 34.47% …
AnaptysBio has announced the dates for post-trial briefings in its Delaware Chancery Court dispute with Tesaro and GlaxoSmithKline regarding a collaboration license. AnaptysBio is seeking a declaration that Tesaro materially breached the agreement and alleges GlaxoSmithKline tortiously interfered. The consolidated trial concluded in July …
Arrowstreet Capital Limited Partnership reduced its stake in AnaptysBio, Inc. by 12.1% in the first quarter, selling 67,624 shares and retaining 492,120 shares valued at approximately $27.3 million. AnaptysBio reported a significant quarterly loss per share of $1.84, missing analyst expectations, despite revenue exceeding …
This article provides a comprehensive stock analysis of AnaptysBio Inc (ANAB) by TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it has received "Buy" ratings from multiple analysts. Despite …
This article provides a risk assessment for AnaptysBio Inc (ANAB), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 5.15, ranking 50 out of 384 in its industry, and a beta value of 0.89, indicating it tends …
This article provides a valuation analysis of AnaptysBio Inc (ANAB), highlighting its current valuation score of 9.19 within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -51.12, and indicates that P/B, P/S, and P/CF ratios have not yet been …
AnaptysBio (ANAB) is expected to announce its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.1252 per share and revenue of $17.3340 million. The company missed earnings estimates in the previous quarter but exceeded revenue forecasts. …
AnaptysBio has transitioned into a royalty management company, concentrating on Jemperli, an oncology drug commercialized by GSK, after eliminating R&D expenses. The company aims for a 95% EBIT margin with over $140 million in net cash, anticipating increased Jemperli royalties and benefiting from high-margin …
Eversept Partners LP significantly reduced its stake in AnaptysBio, Inc. by 77.6% in the first quarter, selling over 93,000 shares and retaining a smaller position valued at $1.5 million. This move comes despite AnaptysBio reporting revenue that exceeded analyst expectations, though it missed on …
This article provides a technical analysis of AnaptysBio Inc (ANAB), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock is currently trading between resistance at $66.44 and support at $45.24, suitable for range-bound swing trading. …
This article provides a detailed breakdown of AnaptysBio Inc's (ANAB) shareholder structure, listing major shareholders by proportion, categorizing shareholders by type, and detailing institutional shareholding data over several quarters. It also includes information on shareholder activity and related ETFs.
Search by ticker symbol or company name and select a result to open its chart.